GET DAILY SIGNALSAurora Cannabis (ACB) Delivers +9% Revenue Growth in Medical Transition
Key Takeaways
- Net revenue rose 9% year over year to C$86.0 million, fueled by record international medical cannabis revenue of C$61.4 million, up 44%.
- Total medical cannabis revenue climbed 17% to C$82.5 million, while the wind-down of consumer cannabis continued as planned.
- Adjusted EBITDA was C$14.0 million, slightly below the prior-year figure of C$15.4 million.
- Net loss from continuing operations narrowed to C$21.1 million from C$27.2 million a year earlier, but free cash flow was a C$17.5 million outflow.
- ACB ended the quarter with roughly C$133 million in cash and short-term investments and no debt.
Earnings Context and Why It Matters
Aurora Cannabis is in the middle of a deliberate transition toward higher-margin global medical cannabis, and this quarter offered a key test of that strategy. Management has framed fiscal 2027 as a transition year, shaped by an April 2026 reduction in Canadian federal reimbursement rates and the planned exit from lower-margin consumer cannabis. The second quarter of fiscal 2027, which ended September 30, 2026, was expected to show sequential improvement in both revenue and adjusted EBITDA over the first quarter. Because ACB generates the majority of its revenue internationally and operates with no debt, investors are watching closely whether overseas growth can offset domestic pressures and keep profitability on track. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Aurora Cannabis reported total net revenue of C$86.0 million for the second quarter of fiscal 2027, up 9% from C$78.8 million in the prior-year period. The standout was international medical cannabis, which reached a record C$61.4 million, a 44% increase driven by stronger patient demand in Germany and Poland. Canadian medical cannabis revenue fell 24% to C$21.2 million, reflecting the federal reimbursement changes, while consumer cannabis revenue declined to C$1.6 million as the company winds down that channel.
Consolidated adjusted gross margin before fair value adjustments was 61%, down from 65% a year earlier, while medical cannabis margin was 62% compared with 69%. Adjusted EBITDA came in at C$14.0 million versus C$15.4 million in the prior year, and adjusted net income was C$3.1 million compared with C$12.0 million. Net loss from continuing operations narrowed to C$21.1 million from C$27.2 million, helped by the absence of prior-year impairment charges. Free cash flow was a C$17.5 million outflow, an improvement from the C$39.9 million outflow a year ago. ACB ended the quarter with about C$133 million in cash, cash equivalents, and short-term investments and no debt. From what I see, the international momentum stands out clearly here.
Market Reaction and Investor Sentiment
Investor attention around Aurora Cannabis is currently split between the quarterly results and an active M&A situation. ACB has entered into an agreement to be acquired by Organigram Global, while Curaleaf has made a competing offer, and Aurora cancelled its originally scheduled November 12 investor conference call, citing the pending transaction. This backdrop has kept sentiment tied as much to deal developments as to operating performance. The record international revenue and debt-free balance sheet support the bull case for Aurora's medical-first pivot, but the modest year-over-year decline in adjusted EBITDA and ongoing negative free cash flow continue to weigh on the earnings narrative. Shares have traded near their 52-week low in recent months, reflecting caution about the pace of the transition and the regulatory-driven domestic headwinds. I’m watching this closely as the M&A process unfolds.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most immediate variable is the proposed combination with Organigram Global and the competing Curaleaf bid. The outcome of this process will likely overshadow near-term operational results and shape how shareholders assess value.
Operationally, investors should track whether international medical momentum continues, particularly in Germany and Poland, and whether the newly acquired Safari Flower Company and its EU-GMP certified facility add the expected export capacity. Management has previously targeted sustained double-digit revenue growth and superior margins over the long term.
Margin trends also matter. The decline in adjusted gross margin reflects domestic pricing pressure and competitive dynamics, so the ability to hold or expand margins as the international mix grows will be a key test. Finally, free cash flow remains negative, making progress toward self-funding operations an important signal to monitor in the coming quarters.
AI Tools in My Research Process
When evaluating names like ACB, I find Tickeron’s AI Screener helpful for quickly identifying comparable opportunities across the sector using technical patterns, fundamentals, and performance metrics. It surfaces ideas more efficiently than manual reviews and supports a structured approach to tracking trends in medical cannabis and related industries.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ACB turns positive, indicating new upward trend
ACB saw its Momentum Indicator move above the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 72 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ACB just turned positive on November 03, 2026. Looking at past instances where ACB's MACD turned positive, the stock continued to rise in 31 of 44 cases over the following month. The odds of a continued upward trend are 70%.
ACB moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ACB crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +24.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 180 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 77 of 116 cases where ACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.
Bearish Trend Analysis
The 10-day RSI Indicator for ACB moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 17 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
ACB broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.629) is normal, around the industry mean (6.379). P/E Ratio (-2.701) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.984) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a licensed producer of medical marijuana in Canada
Industry PharmaceuticalsGeneric
Advertisement